Treatment with a triazole inhibitor of the mitochondrial permeability transition pore fully corrects the pathology of sapje zebrafish lacking dystrophin-Reference-Cited by-同舟云学术

Treatment with a triazole inhibitor of the mitochondrial permeability transition pore fully corrects the pathology of sapje zebrafish lacking dystrophin

Published:2021-03 Issue: Volume:165 Page:105421
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Stocco Anna^ORCID,Smolina Natalia^ORCID,Sabatelli Patrizia,Šileikytė Justina,Artusi Edoardo,Mouly Vincent^ORCID,Cohen Michael,Forte Michael,Schiavone Marco,Bernardi Paolo^ORCID

Funder

Fondation Leducq

Fondazione Telethon

Publisher

Elsevier BV

Subject

Pharmacology

Reference101 articles.

1. Dystrophin: the protein product of the Duchenne muscular dystrophy locus;Hoffman;Cell,1987

2. The structural and functional diversity of dystrophin;Ahn;Nat. Genet.,1993

3. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin;Rybakova;J. Cell Biol.,2000

4. The pathogenesis and therapy of muscular dystrophies;Guiraud;Annu. Rev. Genomics Hum. Genet.,2015

5. Dystrophin as a molecular shock absorber;Le;ACS Nano,2018

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reduction of Mitochondrial Calcium Overload via MKT077-Induced Inhibition of Glucose-Regulated Protein 75 Alleviates Skeletal Muscle Pathology in Dystrophin-Deficient mdx Mice;International Journal of Molecular Sciences;2024-09-13

2. Leucine-Rich Repeat Kinase-2 Controls the Differentiation and Maturation of Oligodendrocytes in Mice and Zebrafish;Biomolecules;2024-07-19

3. Cardiomyopathy in Duchenne Muscular Dystrophy and the Potential for Mitochondrial Therapeutics to Improve Treatment Response;Cells;2024-07-09

4. Zebrafish polg2 knock-out recapitulates human POLG-disorders; implications for drug treatment;Cell Death & Disease;2024-04-20

5. Mitochondria and Reactive Oxygen Species: The Therapeutic Balance of Powers for Duchenne Muscular Dystrophy;Cells;2024-03-26